The outbreak of coronavirus disease 2019 (COVID-19), which began in December 2019, is still ongoing in Korea, with >9,000 confirmed cases as of March 25, 2020. COVID-19 is a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection, and real-time reverse transcription-PCR is currently the most reliable diagnostic method for COVID-19 around the world. Korean Society for Laboratory Medicine and the Korea Centers for Disease Prevention and Control propose guidelines for diagnosing COVID-19 in clinical laboratories in Korea. These guidelines are based on other related domestic and international guidelines, as well as expert opinions and include the selection of test subjects, selection of specimens, diagnostic methods, interpretation of test results, and biosafety.

Invasive fungal infections (IFIs) in Asia/Pacific are a particular threat to patients with malignancies, uncontrolled diabetes mellitus or undiagnosed/untreated human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV/AIDS). Adequate and early access to diagnostic tools and antifungals is essential for IFI clinical management and patient survival. Details on institution profile, self-perception on IFI, and access to microscopy, culture, serology, antigen detection, molecular testing, and therapeutic drug monitoring for IFI were collected in a survey. As of June 2022, 235 centres from 40 countries/territories in Asia/Pacific answered the questionnaire. More than half the centres were from six countries: India (25%), China (17%), Thailand (5%), Indonesia, Iran, and Japan (4% each). Candida spp. (93%) and Aspergillus spp. (75%) were considered the most relevant pathogens. Most institutions had access to microscopy (98%) or culture-based approaches (97%). Furthermore, 79% of centres had access to antigen detection, 66% to molecular assays, and 63% to antibody tests. Access to antifungals varied between countries/territories. At least one triazole was available in 93% of the reporting sites (voriconazole [89%] was the most common mould-active azole), whereas 80% had at least one amphotericin B formulation, and 72% had at least one echinocandin. According to the replies provided, the resources available for IFI diagnosis and management vary among Asia/Pacific countries/territories. Economical or geographical factors may play a key role in the incidence and clinical handling of this disease burden. Regional cooperation may be a good strategy to overcome shortcomings.

Gyu Ri Kim, Ph.D., Eun-Young Kim, Ph.D., Si Hyun Kim, Ph.D., Hae Kyung Lee, M.D., Jaehyeon Lee, M.D., Jong Hee Shin, M.D., Young Ree Kim, M.D., Sae Am Song, M.D., Joseph Jeong, M.D., Young Uh, M.D., Yu Kyung Kim, M.D., Dongeun Yong, M.D., Hyun Soo Kim, M.D., Sunjoo Kim, M.D., Young Ah Kim, M.D., Kyeong Seob Shin, M.D., Seok Hoon Jeong, M.D., Namhee Ryoo, M.D., and Jeong Hwan Shin, M.D.. Ann Lab Med 2023;43:45-54. https://doi.org/10.3343/alm.2023.43.1.45

Heungsup Sung, M.D., Kyoung Ho Roh, M.D., Ki Ho Hong, M.D., Moon-Woo Seong, M.D., Namhee Ryoo , M.D., Hyun Soo Kim, M.D., Jaehyeon Lee, M.D., So Yeon Kim, M.D., Sookwon Yoo, M.D., Mi-Na Kim, M.D., Myung Guk Han, D.V.M., Sang Won Lee, Ph.D., Hyukmin Lee, M.D., and Cheon Kwon Yoo, Ph.D.; on behalf of COVID-19 Diagnosis Test Management Committee established by Korea Centers for Disease Control and Prevention. Ann Lab Med 2020;40:439-47. https://doi.org/10.3343/alm.2020.40.6.439

Park DC, et al. Ann Lab Med. 2019 Nov;39(6):537-544. https://doi.org/10.3343/alm.2019.39.6.537

Ki Ho Hong , M.D., Gab Jung Kim , Ph.D., Kyoung Ho Roh , M.D., Heungsup Sung , M.D., Jaehyeon Lee , M.D., So Yeon Kim , M.D., Taek Soo Kim , M.D., Jae-Sun Park , Ph.D., Hee Jae Huh , M.D., Younhee Park , M.D., Jae-Seok Kim , M.D., Hyun Soo Kim , M.D., Moon-Woo Seong , M.D., Nam Hee Ryoo , M.D., Sang Hoon Song , M.D., Hyukmin Lee , M.D., Gye Cheol Kwon , M.D., and Cheon Kwon Yoo , Ph.D.. Ann Lab Med 2022;42:391-7. https://doi.org/10.3343/alm.2022.42.4.391